SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is currently trending as heightened geopolitical focus on Greenland's strategic rare earth deposits, fueled by U.S. administration commentary, drives conversation. The community is actively discussing the potential for government investment and partnerships to secure a Western-aligned supply chain, with attention on the company's Tanbreez project and upcoming business updates. This surge reflects broader market interest in critical minerals and reducing reliance on key producing nations for essential resources.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amid an intense rally in memory and storage stocks, driven by soaring demand from AI infrastructure buildouts and rising prices for essential components. The community is actively debating if its rapid appreciation reflects a legitimate "memory supercycle" or an "overpriced bubble," with many expressing FOMO while others anticipate a pullback. This strong movement is widely seen as a reflection of the broader sector's response to unprecedented AI-driven data center needs.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid intense community speculation surrounding imminent government contract announcements, especially concerning its secure AI capabilities for defense and potential involvement in TSA modernization. This optimism is fueled by the company's recent strategic debt reduction and the completion of its Ask Sage acquisition, significantly strengthening its financial position and market offerings.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending with significant community enthusiasm, driven by landmark U.S. and U.K. defense contracts, notably an $816 million SDA award, which solidifies its strategic pivot to an end-to-end national security space partner. Investors are keenly focused on its successful Electron launches and the eagerly anticipated Neutron rocket debut, fueling conviction that RKLB is a generational investment in the rapidly expanding space industry.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing a surge in bullish sentiment, driven by significant trading volume and active options flow. The community is buzzing about strong technical signals, anticipating a major breakout past key resistance levels amidst a broader rotation into small-cap technology stocks and improving housing market outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is experiencing a significant uplift following news of an $880 million data center deal in Israel and plans to be an early adopter of NVIDIA's Vera Rubin NVL72 platform. The community is actively discussing this as a major catalyst, fueling optimism for substantial price recovery and long-term growth within the burgeoning AI infrastructure sector, despite the stock's noted volatility.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amidst sharp market volatility, primarily driven by recent downgrades from major financial institutions, which many in the community perceive as a manipulative tactic by competitors to acquire shares at a discount. This intense trading activity is prompting discussions of a strategic buying opportunity for long-term holders, anticipating strong upcoming earnings and potential S&P 500 inclusion, despite frustration over what's seen as repeated institutional tactics.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending due to widespread reports of Eli Lilly nearing a multi-billion dollar acquisition, immediately sparking intense market speculation. This potential buyout highlights the strategic value of Ventyx's NLRP3 inhibitor pipeline, with the community actively discussing a possible bidding war among major pharmaceutical companies for its promising applications in chronic inflammatory, cardiometabolic, and neurodegenerative diseases. Many investors see Ventyx's assets as a crucial complementary class to the thriving GLP-1 market, also fueling strong short squeeze sentiment.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending due to highly positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in plaque psoriasis, which demonstrated strong skin clearance and a favorable safety profile. This breakthrough has prompted significant analyst price target increases and robust community discussion, with many anticipating the drug to be a best-in-class contender in a lucrative market. While some debate potential future offerings, the company's solid cash position and pipeline for other immune-mediated diseases like lupus are fueling bullish sentiment among traders.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing increased trading volume and positive gains, distinguishing itself amidst broader crypto market optimism and predictions for an altcoin season. The community is actively discussing its foundational utility in decentralized AI, DePIN, and secure data monetization via its Layer-2 network, supported by strong regulatory standing in Japan and ex-Sony leadership. This strategic positioning and technical breakouts are fueling bullish sentiment for significant growth, though some long-term investors remain cautious due to historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>UBS reiterated its Neutral stance on Nike, citing strong brand equity but a prolonged recovery timeline.</li><li>It believes Nike’s brand strength should support a long-term recovery.</li></ul>Shares of Nike (<a href="https://stocktwits.com/symbol/NKE">NKE</a>) were in the spotlight on Friday after UBS analyst Jay Sole said Nike’s brand remains strong, which will help the sportswear firm turn around its ongoing struggles; however, the turnaround will take longer than the market expects.As per TheFly, UBS said in a note that it continues to believe Nike's business will improve. It rated the stock as “Neutral,” saying that the rating reflects the view that the company's turnaround will take longer than the market expects. UBS maintained a $62 price target on Nike shares.<h2 class="st-heading-2">Turbulent Few Years</h2>Nike has seen leadership changes, management resets, excess inventory, and renewed focus on innovation, leading to a slow, uneven turnaround under scrutiny.Nike has worked to clean up excess inventory, particularly by reducing production of legacy franchises such as Air Jordans and Air Force 1s. While the reset pressured near-term results, the company said in December that inventory levels are now healthy across North America, EMEA, and other key regions.<h2 class="st-heading-2">Struggles In China</h2>The struggle in China has been longstanding for Nike, as it is continuing to face steep competition from other retailers. The recent tariff war between the two largest economies has further slowed Nike’s efforts to gain market share in China’s booming outdoor sports market.Nike, in its recently reported second-quarter results, said its footwear sales in China fell 21%, and overall sales fell 17% to $1.42 billion. The China region accounts for nearly 15% of Nike’s annual revenue.<h2 class="st-heading-2">Tim Cook’s Vote Of Confidence</h2>Apple CEO Tim Cook has, time and again, through strategic shifts, market scepticism, and operational missteps, publicly and privately reinforced his confidence in Nike, lending credibility when the brand needed it most.Cook has been on Nike’s board since 2005. He recently echoed his long-standing relationship with Nike after it made an open-market purchase of about $3 million worth of the company’s stock, a personal investment.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on NKE trended in ‘extremely bullish’ amid ‘high’ message levels.<figure class="image"><img style="aspect-ratio:638/65;" src="https://news.stocktwits-cdn.com/NKE_Sentiment_PNG_da214e3bac.webp" alt="Retail sentiment on NKE trended in ‘extremely bullish’ amid ‘high’ message levels." width="638" height="65"></figure> For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A garden in the shape of a Nike corporate logo is seen in an office building patio in midtown Manhattan on April 6, 2023, in New York City. (Photo by Gary Hershorn/Getty Images)

Nike Turnaround Faces A Longer Road Despite Brand Strength, UBS Says 

It maintained a $62 price target as inventory, China weakness, and competition weigh on momentum.

Equity

It maintained a $62 price target as inventory, China weakness, and competition weigh on momentum.


<ul class="summary-bullets"><li>UNH raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16.&nbsp;</li><li>However, company executives warned on the company’s earnings call that the path to recovery in its Medicaid business will be challenging.</li><li>They noted that medical cost trends remain historically high but consistent with the company’s second-quarter guidance.&nbsp;</li></ul>UnitedHealth Group (UNH) on Tuesday raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16, as it seeks to return to growth in 2026.“We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect solid execution toward that goal,” said CEO Stephen Hemsley.“Simply put, we will end 2025 well-positioned for a return to solid growth in 2026, acceleration in 2027, and a clear focus on our long-standing mission and strategy,” the CEO noted during the company’s third quarter (Q3) earnings call, while adding that the company intends to share its 2026 full guidance in January with its fourth quarter (Q4) earnings.Hemsley took over the reins of the company in May after former CEO Andrew Witty stepped down. He is also the chairman of UNH’s board of directors.<h2 class="st-heading-2">Execs Flag Concerns On Medicaid Business Recovery</h2>However, company executives warned on the earnings call that the path to recovery for the company’s Medicaid business will be challenging. Medicaid is a joint federal and state program in the United States that provides low-cost or free health coverage to eligible low-income individuals.“States have not funded in line with actual cost trends, so funding levels are not sufficient to cover the health needs of state enrollees. While we're making steady progress in bridging this gap with states, the mismatch between rate adequacy and member acuity will likely extend through 2026," Hemsley said, according to an earnings call transcript provided by Fiscal AI. A company executive also noted that the elevated cost trends in the business were driven by specialty pharmacy, behavioral health, and home health services in the third quarter.<h2 class="st-heading-2">UnitedHealth’s Q3 Numbers</h2>For the third quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.unitedhealthgroup.com/newsroom/2025/2025-10-28-uhg-reports-third-quarter-2025-results-and-raises-full-year-2025-earnings-outlook.html">reported</a> a 12% increase in consolidated revenue to $113.2 billion, above an analyst estimate of $113.06 billion, as cited by Fiscal AI.Adjusted earnings per share came in at $2.92, above an expected $2.81.Medical cost ratio, or the percentage of premiums used on medical care, was 89.9%, in line with the expectations put forth by the company in the second quarter (Q2). Company executives noted on the earnings call that medical cost trends remain historically high but consistent with its second quarter guidance, and the insurer expects that to continue throughout the remainder of 2025.The company’s revenue from its key Optum business segment, meanwhile, grew 8% year-over-year to $69.2 billion.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/UNH">UNH stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock yielding significant profits in the future.<stembedurl>https://stocktwits.com/_Texan_/message/634014037</stembedurl>Another user resonated the sentiment.<stembedurl>https://stocktwits.com/Smoothbrainape/message/634012667</stembedurl>UNH stock is down by 27% this year and by about 34% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-on-look-out-for-manufacturing-engineer-to-advance-new-roadster-sports-ev/cLGjVUAR3vE">Tesla On The Look-Out For Manufacturing Engineer To Advance Its New Roadster Sports EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the UnitedHealth Group logo is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

UnitedHealth Increases Full Year Earnings Forecast But Warns Of Tough Road Ahead For Medicaid Business

UNH raised its full-year adjusted earnings guidance to at least $16.25 per share, up from its previous outlook of at least $16. 

First Trust Exchange-Traded Fund VI - First Trust S&P 500 Diversified Dividend Aristocrats ETF

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$36.96
Prev Close	$36.26
Open	$36.82
Dividend Yield	N/A
50-Day Moving Average	$35.57
Beta	N/A
Avg. Volume	8,966.91
PE Ratio	N/A

52-Week High	$37.01
52-Week Low	$27.61
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

KNGZ
First Trust Exchange-Traded Fund III - First Trust US Equity Dividend Select ETF

Feed

News

Sentiment

Fundamentals

Info

Latest KNGZ News

KNGZFirst Trust Exchange-Traded Fund III - First Trust US Equity Dividend Select ETF